Forte Biosciences | 4: Statement of changes in beneficial ownership of securities-Director GRYSKA DAVID W
Forte Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Eichenfield Lawrence
Forte Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Kornfeld Steven
Forte Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Doberstein Stephen K
Forte Biosciences | 4: Statement of changes in beneficial ownership of securities-Director FINCK BARBARA K
Forte Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Brun Scott C.
Forte Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Williams Donald Allen
Forte Biosciences | 8-K: Current report
Forte Biosciences | 8-K: FORTE BIOSCIENCES, INC. ANNOUNCES SECOND QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE
Forte Biosciences | 10-Q: Q2 2024 Earnings Report
Forte Biosciences | DEF 14A: Definitive information statements
Forte Biosciences | ARS: Annual Report to Security Holders
Forte Biosciences | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Forte Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Riley Antony A
Forte Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Wagner Paul A.
Forte Biosciences | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ATG Fund II LLC(4.0%),ATG Capital Management, LLC(4.0%), etc.
Forte Biosciences | 8-K: Current report
Forte Biosciences | 10-Q: Q1 2024 Earnings Report
Forte Biosciences | 8-K: FORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE
Forte Biosciences | 10-K/A: Annual report (Amendment)
No Data